arrow
C

Corrado Bernasconi

University of Bern
H指数:34
被引数:5,705

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enhanced Risk Stratification of Atrial Fibrillation Detected After Ischemic Stroke and TIA: The Role of Apnoea–Hypopnoea Index and Hypoxic Burden—A Study From the Bern Sleep-Stroke Registry

缺血性卒中及短暂性脑缺血发作后检测到的心房颤动的风险分层增强:呼吸暂停-低通气指数和缺氧负荷的作用——一项来自伯尔尼睡眠-卒中登记研究

2026-04-260
OAAI
Narcolepsy type 2 is an unstable diagnosis and idiopathic hypersomnia has the potential for remission-long-term and cross-sectional observations from the Bern Sleep-Wake Registry

发作性睡病2型是一种不稳定的诊断,而特发性嗜睡具有潜在的缓解可能性——来自伯尔尼睡眠-觉醒注册登记系统的长期和横断面观察

SLEEP
IF4.9
2025-09-011
PRE
Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial)

帕金森病患者静脉注射脂质体GM1的安全性及耐受性:一项单中心开放标签临床I期试验(NEON试验)

2025-05-130
OA
Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials

奥法木单抗与干扰素β-1a在复发型多发性硬化中的认知效应比较:OPERA I/II试验的事后分析

2025-03-010
PRE
Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study

在Floodlight Open中使用基于智能手机的多发性硬化症远程评估,一项全球性,前瞻性,开放获取研究

2024-01-028
OAAI
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
2023-07-0126
OAAI